Document is current
Any future updates will be listed below
-
Authors
Konstantinidou, Markella https://orcid.org/0000-0001-5972-4140
Zingiridis, Marios https://orcid.org/0009-0008-1150-2926
Pennings, Marloes A. M. https://orcid.org/0000-0002-3366-0238
Fragkiadakis, Michael
Virta, Johanna M.
Revalde, Jezrael L. https://orcid.org/0000-0002-8794-6784
Visser, Emira J.
Ottmann, Christian https://orcid.org/0000-0001-7315-0315
Brunsveld, Luc https://orcid.org/0000-0001-5675-511X
Neochoritis, Constantinos G. https://orcid.org/0000-0001-5098-5504
Arkin, Michelle R. https://orcid.org/0000-0002-9366-6770
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM147696)
Ono Pharma Foundation Breakthrough Science Initiative Award
Netherlands Organisation for Scientific Research | Stichting voor de Technische Wetenschappen (Gravity program 024.001.035)
ENW M-grant OCENW.M20.200
Foundation for Research and Innovation (H.F.R.I.) under the ‘‘2nd Call for H.F.R.I. Research Projects to support Post-Doctoral Researchers’’ (Project Number: 0911) Empeirikion Idryma
- License Information
-
More Information
Article History
Received: 17 February 2025
Accepted: 3 June 2025
First Online: 14 July 2025
Competing interests
: Michelle R. Arkin, Christian Ottmann, and Luc Brunsveld are co-founders of Ambagon Therapeutics. M.K., M.Z., M.F., C.G.N,. and M.R.A. are co-inventors on a patent application related to this work. The remaining authors declare no competing interests.
